GlassScriptPhysician profile
Aniket Saha
NPI 1871749176
$1,302.40
in general payments reported to CMS, 2019-2025
18 companies · $70.55 in 2025
The $70.55 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $255 · 2021: $248 · 2022: $196 · 2023: $31.39 · 2024: $164 · 2025: $70.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $247.72 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $225.00 | 2019-2022 | |
| Novo Nordisk INC | $170.78 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $115.98 | 2024 | Rezlidhia, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $114.08 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $109.79 | 2019 | |
| Karyopharm Therapeutics INC. | $70.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $63.88 | 2019-2024 | |
| Adaptive Biotechnologies Corporation | $33.77 | 2025 | Clonoseq |
| Pierre Fabre Pharmaceuticals, INC. | $32.75 | 2023-2025 | Hemangeol |
| Pfizer INC. | $28.19 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.26 | 2025 | Koselugo |
| Silvergate Pharmaceuticals, INC. | $17.00 | 2019 | |
| Csl Behring | $15.65 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.74 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emmaus Medical, INC. | $12.41 | 2019 | |
| Octapharma USA, INC. | $11.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aniket Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.